Core Insights - Novo Nordisk (NVO) received FDA approval for Wegovy pill (once-daily oral semaglutide 25 mg) aimed at reducing excess body weight and maintaining weight loss long-term, while also lowering the risk of major adverse cardiovascular events [2][8] - The approval of the oral formulation represents a significant milestone as it is the first GLP-1 RA approved in oral form for weight management, providing a more convenient administration option compared to injectable forms [4][12] Clinical Efficacy - The FDA approval was based on robust late-stage clinical evidence from the phase III OASIS development program, which included four studies with approximately 1,300 obesity patients [5] - In the key OASIS 4 study, patients treated with the Wegovy pill achieved a mean weight reduction of 16.6%, with one in three patients losing 20% or more of their body weight [6][8] - The safety and tolerability profile of the oral Wegovy was consistent with previous semaglutide studies, reinforcing confidence in its use [6] Market Dynamics - NVO's Wegovy pill is set to launch in the U.S. market in early January 2026, with regulatory applications submitted for approval in the EU and other global health authorities in the second half of 2025 [10] - The obesity treatment market is highly competitive, with Novo Nordisk and Eli Lilly (LLY) as the primary players, and the approval of the oral Wegovy pill may shift competitive dynamics back in favor of Novo Nordisk [11][12] - Eli Lilly is also developing next-generation drugs, including oral and injectable medications, which could intensify competition in the obesity treatment space [13][14] Future Developments - Novo Nordisk is advancing another candidate, amycretin, for weight management, with plans to initiate a phase III program in the first quarter of 2026 [12] - Smaller biotech firms, such as Viking Therapeutics and Structure Therapeutics, are also developing GLP-1-based therapies, indicating a growing competitive landscape in the obesity treatment market [15][16]